Proteomics, in which Australians are pioneers, can no longer be described as an emerging discipline, writes Graeme O'Neill. [ + ]

Australia's biotechnology industry is tiny by comparison with its US and European counterparts, but it offers glimpses of what a future in which most cancers will be curable, or ideally, preventable, writes Graeme O'Neill. [ + ]

When the Victorian Department of Agriculture's Werribee research farm advertised for a 'Semi-Dwarf Wheat Breeder' in the early 1970s, Bryan Whan applied -- his qualifications measured up, even if his height exceeded specification. [ + ]

From wine to wheat to mouse plagues, Australian life scientists are nothing if not creative in agricultural biotech, writes Graeme O'Neill. [ + ]

Positive forces are at work in Australian venture capital circles, writes Renate Krelle. [ + ]

The secret's out -- Australia is a great place to do clinical trials and contract research, as Renate Krelle discovers. [ + ]

UK and European biotechs may not have heard of Australian historian Geoffrey Blainey. But Harry Karelis, of Sydney venture capitalist Biotech Capital, says both British and continental biotechs are just as conscious as Australians are of Blainey's most famous concept -- the tyranny of distance. [ + ]

Dr Andy Gearing believes wholeheartedly that big pharma and big biotech overseas should take a closer look at what the Australian biotechnology and life sciences sector has to offer. [ + ]

Australia's research institutes and industry have a mutual responsibility, says Prof John Mattick -- to work together to translate academic ideas into ideas for development and commercialisation. [ + ]

A keen fascination in the creative ideas of others and a willingness to take risks are hallmarks of Australian biotechnology entrepreneur Dr Mervyn Jacobson's outlook on life. [ + ]

The patents keep rolling in for Perth biotech-nanotech company Psivida (ASX:PSD), which has announced that the European Patent Office (EPO) has granted its UK operating subsidiary pSiMedica another patent on biodegradable silicon implants for drug delivery. [ + ]

Start-ups are the easy bit -- it's the quality and consistency of post-natal care that determines whether young biotechnology companies will survive, according to Dr Jurgen Michaelis, the man behind the rapid rise of South Australia's biotechnology industry. [ + ]

Melbourne-based equipment manufacturer Vision Biosystems, part of the Vision Systems group (ASX:VSL), has launched its Peloris tissue processor in Australia, and plans to launch the instrument in international markets as well. [ + ]

Prana (ASX: PBT; NASDAQ: PRAN) shareholders today gave the stamp of approval to the company's AUD$28 million capital raising, voting in favour of the sale to US institutional investors of 3 million ADRs at US$5 per ADR. [ + ]

One of the most serendipitous moments in the recent history of Australian biobusiness occurred when Alison Coutts met Mark Fordree, Iain Scott learns. [ + ]